Patents by Inventor Shomir Ghosh

Shomir Ghosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120088793
    Abstract: Disclosed herein are compounds that may be modulators of 5-HT receptors, and methods of making and using same.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Inventors: Shomir Ghosh, Gali Golan, Boaz Inbal, Vincent Jacques, Mercedes Lobera
  • Publication number: 20120046311
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: September 26, 2011
    Publication date: February 23, 2012
    Applicant: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Patent number: 8114894
    Abstract: Disclosed herein are compounds that may be modulators of 5-HT receptors, and methods of making and using same.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: February 14, 2012
    Assignee: Nanotherapeutics, Inc.
    Inventors: Shomir Ghosh, Gali Golan, Boaz Inbal, Vincent Jacques, Mercedes Lobera
  • Patent number: 8067415
    Abstract: The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: November 29, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Amy M. Elder, Shomir Ghosh, Sian Griffiths, Prakash Raman, Francois Soucy, Kevin Sprott, Qing Ye
  • Patent number: 8067457
    Abstract: The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: November 29, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shomir Ghosh, Prakash Raman, Kevin Sprott, Amy M. Elder, Sian Griffiths, Francois Soucy, Qing Ye
  • Patent number: 8063222
    Abstract: The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein R1, X, Z, R2, X1, Ar, n, R3 and R4 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR8 and accordingly are useful for the treatment of a variety of inflammatory and allergic disorders.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: November 22, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Mingshi Dai, Bing Guan, Robert A. Bennett, Douglas F. Burdi, Shomir Ghosh, Gang Li, Charles A. Minor, Tracy J. Jenkins
  • Publication number: 20110281873
    Abstract: Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.
    Type: Application
    Filed: December 11, 2009
    Publication date: November 17, 2011
    Inventors: Phoebe Chiang, Shomir Ghosh
  • Patent number: 8058287
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: November 15, 2011
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Publication number: 20110263588
    Abstract: The present invention relates to compounds that may be negative allosteric modulators of metabotropic receptors-subtype 5, and methods of making and using same.
    Type: Application
    Filed: October 23, 2009
    Publication date: October 27, 2011
    Applicant: GLAXO GROUP LIMITED
    Inventors: Peter Bertinato, Merav Fichman, Shomir Ghosh, Jian Lin, Dalia Segal, Zhaoda Zhang
  • Publication number: 20110237601
    Abstract: The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
    Type: Application
    Filed: December 17, 2010
    Publication date: September 29, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Prakash Raman, Francois Soucy, Qing Ye, Shomir Ghosh
  • Publication number: 20110230494
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 1, 2011
    Publication date: September 22, 2011
    Applicant: AVILA THERAPEUTICS, INC.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Publication number: 20110230516
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 22, 2011
    Inventors: Kenneth G. Carson, Geraldine C.B. Harriman, Shomir Ghosh
  • Publication number: 20110224432
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 1, 2011
    Publication date: September 15, 2011
    Applicant: AVILA THERAPEUTICS, INC.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Patent number: 7989465
    Abstract: The present invention provides 4,6-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable salts and compositions thereof, and methods of using the same. The present invention also provides probe compounds, such as compounds of formula V: wherein each of Ring A, Ring B, R1?, T, Rt, m, Rx, Ry, and W is described herein.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: August 2, 2011
    Assignee: Avila Therapeutics, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Patent number: 7982036
    Abstract: The present invention provides compounds of formula I wherein Ring A, Ring B, m, Rx, Ry, W and R1 are as defined herein, pharmaceutically acceptable salts and compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: July 19, 2011
    Assignee: Avila Therapeutics, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Patent number: 7977350
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: July 12, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • Patent number: 7951950
    Abstract: Disclosed are CRTH2 inhibitors represented by Structural Formula (I): The values for the variables of Structural Formula (I) are provided herein.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: May 31, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Jeremy D. Little, Shomir Ghosh, Sean Harrison, Amy M. Elder, Christelle C. Renou, Kenneth G. Carson
  • Publication number: 20110117073
    Abstract: The invention relates to protein conjugates that contain a protein kinase containg a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Application
    Filed: September 15, 2010
    Publication date: May 19, 2011
    Applicant: Avila Therapeutics, Inc.
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Publication number: 20110046362
    Abstract: The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as cystic fibrosis and upper respiratory disorders.
    Type: Application
    Filed: February 13, 2009
    Publication date: February 24, 2011
    Inventors: Carmen M. Baldino, Dan P. Cook, Shomir Ghosh, Lazlo Varady, Thomas Andreas Waldbach, Zhongguo Wang
  • Patent number: 7880002
    Abstract: The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
    Type: Grant
    Filed: December 28, 2005
    Date of Patent: February 1, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Prakash Raman, Francois Soucy, Qing Ye, Shomir Ghosh